Skip to main content

Table 3 Patients with hemoglobin concentrations within 9.5 to 13.0 g/dL

From: An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients

Interval

Cohort A

Cohort B

Cohort C

Cohort D

Cohort E

Cohort F

Cohort G

Cohort H

Total l

Cohorts With an ESA- Free Interval (D, E, F)

Cohorts Without an ESA- Free Interval (A, B, C, G, H)

Weeks 2–13, n

14

15

12

25

15

13

25

29

148

53

95

no. (%)

9 (64.3)

12 (80.0)

9 (75.0)

21 (84.0)

11 (73.3)

11 (84.6)

20 (80.0)

18 (62.1)

111 (75.0)

43 (81.1)

68 (71.6)

Weeks 14-25, n

6

10

10

25

13

13

24

26

127

51

76

no. (%)

5 (83.3)

9 (90.0)

6 (60.0)

21 (84.0)

12 (92.3)

10 (76.9)

21 (87.5)

16 (61.5)

100 (78.7)

43 (84.3)

57 (75.0)

  1. First row of each set indicates the total number of patients, second row, the number within range and the percentage.